Zydus Lifesciences Limited (NSE: ZYDUSLIFE) has unveiled new post hoc analysis from the pivotal Phase 3 EPICS-III trial of saroglitazar, showing greater biochemical response compared to placebo across geographic subgroups in patients with primary biliary cholangitis (PBC). The findings were presented at the American College of Gastroenterology (ACG) 2026 Annual Meeting.

Greater Biochemical Response in U.S. Subgroup

Numerically higher biochemical response treatment difference was observed in the U.S. subgroup relative to the non-U.S. subgroup (∆ 60.7% vs. ∆ 41.6%) in patients with PBC. These results build on the clinical profile of saroglitazar in patients with PBC who have inadequate response or intolerance to ursodeoxycholic acid (UDCA).

EPIC-III Trial Overview

The EPICS-III trial is a multicenter, randomized, double-blind, placebo-controlled, seamless Phase 2(b)/3 trial evaluating the efficacy and safety of saroglitazar in patients with PBC who had an inadequate response to or intolerance of UDCA. The trial included nearly thirty percent of patients from the U.S. and composite biochemical response rates were greater with saroglitazar than placebo in both U.S. (60.7% vs. 0%) and non-U.S. subgroup regions (55.1% vs. 13.5%). Saroglitazar was generally well tolerated, with adverse events generally balanced between saroglitazar-treated and placebo-treated patients.

As a result, Zydus Therapeutics plans to launch saroglitazar in the United States by March 2027 if approved by the FDA. These findings provide additional insight into the Phase 3 EPICS-III results and the biochemical responses observed among patients enrolled in different geographic regions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zydus Lifesciences Limited

Zydus Lifesciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Zydus holds in the upper half of its 52-week range, a sign the market backs the stock. The PEG of 0.68 signals undervaluation relative to growth. It is a potential re-rating candidate. The business compounds revenue at 16.5% and profits at 37.0% CAGR. That is strong double-digit growth on both counts. The stock trades at 75% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Revenue grows at 16.5% and profits at 37.0%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Zydus Lifesciences Limited.

Wanbury Limited, a pharmaceutical company with a global API presence and domestic branded formulations portfolio, announced the launch of its berrysoft™ baby product range across multiple states in India through its subsidiary Wanbury Skin Health Limited. The launch marks a strategic entry into the paediatric dermatology segment.

Strategic Expansion

The berrysoft™ baby range has been developed to address everyday baby skincare and hygiene needs. The product portfolio includes Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, Syndet Handwash, Moisturising Lotion, Diaper Rash Cream, and Moisturising Cream in the pipeline. This initiative reflects Wanbury Limited’s focus on expanding its overall healthcare portfolio through its various subsidiaries.

Market Presence

Wanbury Skin Health Limited has received GST registration in five states including Maharashtra, Delhi, and Karnataka, with three more in pipeline. The company also has received CFA Drug Licenses in Mumbai, Jaipur, Patna, and Ambala, with four more in pipeline. This multi-state launch marks an important milestone in Wanbury Limited’s growth strategy, combining portfolio diversification with deeper engagement across its existing healthcare professional network.

Future Prospects

Wanbury Limited aims to leverage established market relationships to drive growth in complementary product categories and strengthen its presence across relevant healthcare segments. The company will continue to explore opportunities to broaden its product portfolio and strengthen its presence across relevant healthcare categories.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Wanbury Limited

Wanbury Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Wanbury drops 34.0% over three months and trades near its 52-week lows. Thin margins at 8.6% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 20 of recent sessions versus 10 for buyers, so the pressure has not fully lifted. Revenue grows at 8.9% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Wanbury Limited.

Dr. Reddy’s Laboratories Limited (DRREDDY) is set to release its financial results for the quarter and six months ended September 30th, 2026 on Friday, October 23rd. The announcement will focus on key earnings and revenue insights. The company will hold an earnings call at 19:30 PM IST / 10:00 AM ET to discuss the financial performance. The call will be hosted by the company and can be accessed via the provided link for registration. This event marks a significant moment for investors and stakeholders to gain a deeper understanding of the company’s financial health and future prospects.

Financial Performance Overview

The upcoming release will provide detailed insights into Dr. Reddy’s Laboratories’ financial performance for Q2FY27. Notably, the company’s earnings and revenue are expected to reflect its strategic initiatives and market dynamics. The earnings call will offer a platform for management to elaborate on these aspects, highlighting key metrics and future growth strategies.

Investor Engagement

Investors are encouraged to participate in the earnings call to gain direct insights from the company’s leadership. The call will be available in audio format, with a transcript also accessible on the company’s website. This engagement is crucial for understanding the company’s current standing and future trajectory in the pharmaceutical sector.

As Dr. Reddy’s Laboratories Limited prepares to unveil its Q2FY27 results, the focus remains on delivering valuable financial insights that will guide stakeholders in making informed decisions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Dr. falls 10.4% over three months and has not found a floor yet. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. Revenue contracts at 11.0% CAGR. That signals structural headwinds, not a short-term blip. The stock gains 5.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. The stock rises -10.4% in three months on 11.0% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Dr. Reddy’s Laboratories Limited.